Avadel Pharmaceuticals logo

Avadel PharmaceuticalsNASDAQ: AVDL

Profile

Sector:

Healthcare

Country:

Ireland

IPO:

07 June 1996

Next earnings report:

04 March 2025

Last dividends:

N/A

Next dividends:

N/A
$1.03 B
-43%vs. 3y high
74%vs. sector
-vs. 3y high
-vs. sector
-40%vs. 3y high
95%vs. sector
-99%vs. 3y high
72%vs. sector

Price

after hours | Mon, 18 Nov 2024 21:20:00 GMT
$10.71-$0.04(-0.33%)

Dividend

No data over the past 3 years
$50.02 M$53.07 M
$50.02 M-$2.63 M

Analysts recommendations

Institutional Ownership

AVDL Latest News

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
globenewswire.com13 November 2024 Sentiment: POSITIVE

DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET.

Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript
seekingalpha.com12 November 2024 Sentiment: NEUTRAL

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - CEO Richard Kim - CCO Jennifer Gudeman - SVP, Medical & Clinical Affairs Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Oren Livnat - H.C. Wainwright Ami Fadia - Needham David Amsellem - Piper Sandler Operator Good day everyone and welcome to today's Avadel Pharmaceuticals 3Q 2024 Earnings Call.

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
globenewswire.com17 October 2024 Sentiment: POSITIVE

-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy—

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)
globenewswire.com03 September 2024 Sentiment: POSITIVE

– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens –

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
globenewswire.com28 August 2024 Sentiment: POSITIVE

DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?
zacks.com05 August 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Avadel Pharmaceuticals to Join Russell 3000® Index
globenewswire.com27 June 2024 Sentiment: POSITIVE

DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
globenewswire.com22 May 2024 Sentiment: POSITIVE

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –

Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
Zacks Investment Research29 April 2024 Sentiment: POSITIVE

The average price target set by analysts on Wall Street suggests a potential 28.6% increase in Avadel (AVDL). Although the reliability of this metric is uncertain, the positive trend in earnings estimates revisions could lead to a rise in the stock.

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Seeking Alpha02 April 2024 Sentiment: POSITIVE

Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel's ability to navigate challenges.

  • 1(current)

What type of business is Avadel Pharmaceuticals?

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

What sector is Avadel Pharmaceuticals in?

Avadel Pharmaceuticals is in the Healthcare sector

What industry is Avadel Pharmaceuticals in?

Avadel Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Avadel Pharmaceuticals from?

Avadel Pharmaceuticals is headquartered in Ireland

When did Avadel Pharmaceuticals go public?

Avadel Pharmaceuticals initial public offering (IPO) was on 07 June 1996

What is Avadel Pharmaceuticals website?

https://www.avadel.com

Is Avadel Pharmaceuticals in the S&P 500?

No, Avadel Pharmaceuticals is not included in the S&P 500 index

Is Avadel Pharmaceuticals in the NASDAQ 100?

No, Avadel Pharmaceuticals is not included in the NASDAQ 100 index

Is Avadel Pharmaceuticals in the Dow Jones?

No, Avadel Pharmaceuticals is not included in the Dow Jones index

When was Avadel Pharmaceuticals the previous earnings report?

No data

When does Avadel Pharmaceuticals earnings report?

The next expected earnings date for Avadel Pharmaceuticals is 04 March 2025